We wrote about Somanetics (SMTS) on Feb. 28th here The Long Case for Somanetics, and felt that a good buying opportunity existed in the mid teens. On Wednesday March 17th, the company announced first quarter results. The results beat the analyst estimates handily and the company guided sales higher for the year. The stock reacted by appreciating 19%.
We'll continue to monitor SMTS throughout the year and give important updates as they occur. As for now, things look bullish for this small cap medical technology company. Thank you for reading.
No comments:
Post a Comment